Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genprex, Inc.GNPX · Entity 8441 | Director | February 12, 2019 | February 21, 2019 |
| Marker Therapeutics, Inc.TPIV · Entity 7609 | Director · President and COO | March 09, 2017 | March 13, 2017 |
| Qrons Inc.QRON · Entity 121346 | Chief Operating Officer | July 01, 2019 | July 02, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genprex, Inc.
Report date February 12, 2019 · Filed February 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2029-02-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-02-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: (1) One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of (a) the one (1) year anniversary of February 12, 2019 and (b) the day prior to the next annual meeting of Genprex, Inc. stockholders occurring after February 12, 2019, in each case, provided that the optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: (1) One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of (a) the one (1) year anniversary of February 12, 2019 and (b) the day prior to the next annual meeting of Genprex, Inc. stockholders occurring after February 12, 2019, in each case, provided that the optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.
Marker Therapeutics, Inc.
Report date March 09, 2017 · Filed March 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,054 |
Reported balance
After 2017-03-09 transaction · row 1
1 source rowRow 1 · 2017-03-09 · Grant · Acquired 5,220 · Balance 26,054 F1: Represents the portion of a discretionary bonus award for 2016 payable as a restricted, immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan. The issuance of 5,220 shares of restricted common stock was based on the closing price or our common stock of $4.31 per share, on the day immediately preceding the date the 2016 bonus award was approved. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 10,417 |
Reported balance
Holding disclosure · report date 2017-03-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,417 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the portion of a discretionary bonus award for 2016 payable as a restricted, immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan. The issuance of 5,220 shares of restricted common stock was based on the closing price or our common stock of $4.31 per share, on the day immediately preceding the date the 2016 bonus award was approved.
Qrons Inc.
Report date July 01, 2019 · Filed July 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,500 |
Reported balance
Holding disclosure · report date 2019-07-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 37,500 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-07-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: 50,000 shares subject to the option are exercisable on July 1, 2019 and expire on July 1, 2022; 25,000 shares subject to the option are exercisable on July1, 2020 and expire on July 1, 2023; and 25,000 shares subject to the option are exercisable on July 1, 2021 and expire on July 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: 50,000 shares subject to the option are exercisable on July 1, 2019 and expire on July 1, 2022; 25,000 shares subject to the option are exercisable on July1, 2020 and expire on July 1, 2023; and 25,000 shares subject to the option are exercisable on July 1, 2021 and expire on July 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2017 Filed Mar 13, 2017 20:01 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 5,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-014231 · v461691_4.xml · nonDerivative · entry 1 BONFIGLIO JOHN N · CIK 0001222253 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,054 F1 · shares: Represents the portion of a discretionary bonus award for 2016 payable as a restricted, immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan. The issuance of 5,220 shares of restricted common stock was based on the closing price or our common stock of $4.31 per share, on the day immediately preceding the date the 2016 bonus award was approved. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 21:31 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,417 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001144204-16-139495 · v455027_4.xml · derivative · entry 4 BONFIGLIO JOHN N · CIK 0001222253 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,416 Underlying: Common Stock · 10,417 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents a partial exercise of a stock option award under the Company's 2014 Omnibus Stock Ownership Plan (the "Plan") originally granted in connection with services to the Company as a consultant. The options fully vested on January 31, 2016. In connection with the exercise of the options, Reporting Person transferred the shares to his spouse. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 21:31 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GiftCommon Stock | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-16-139495 · v455027_4.xml · nonDerivative · entry 3 BONFIGLIO JOHN N · CIK 0001222253 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 10,417 F1 · shares: Represents a partial exercise of a stock option award under the Company's 2014 Omnibus Stock Ownership Plan (the "Plan") originally granted in connection with services to the Company as a consultant. The options fully vested on January 31, 2016. In connection with the exercise of the options, Reporting Person transferred the shares to his spouse. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 21:31 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GiftCommon Stock | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-16-139495 · v455027_4.xml · nonDerivative · entry 2 BONFIGLIO JOHN N · CIK 0001222253 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,834 F1 · shares: Represents a partial exercise of a stock option award under the Company's 2014 Omnibus Stock Ownership Plan (the "Plan") originally granted in connection with services to the Company as a consultant. The options fully vested on January 31, 2016. In connection with the exercise of the options, Reporting Person transferred the shares to his spouse. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 21:31 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | Exercise / conversionCommon Stock | 10,417 | $1.74 | $18,125.58 |
DisclosureSEC source: 0001144204-16-139495 · v455027_4.xml · nonDerivative · entry 1 BONFIGLIO JOHN N · CIK 0001222253 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents a partial exercise of a stock option award under the Company's 2014 Omnibus Stock Ownership Plan (the "Plan") originally granted in connection with services to the Company as a consultant. The options fully vested on January 31, 2016. In connection with the exercise of the options, Reporting Person transferred the shares to his spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.